In short
LIB-01 Monohydrate is an investigational drug currently being studied for the treatment of erectile dysfunction (ED) in adult men. This article explores the ongoing clinical trials, their objectives, and potential benefits of this new medication in addressing a common men's health issue.
At a glance
- Drug Name
- LIB-01 Monohydrate
- Condition Studied
- Erectile Dysfunction (ED)
- Trial Phase
- Phase 2a
- Trial Design
- Randomized, Double-blind, Parallel, Placebo-controlled
- Dosage Forms
- Oral suspension: 10 mg, 25 mg, 50 mg
- Treatment Duration
- 3 days
- Primary Objectives
- Evaluate efficacy and safety of LIB-01 in treating ED
- Key Assessments
- IIEF-EF score, SEP, GAQ, Safety parameters
- Participant Age Range
- 25 to 65 years
- Total Trial Duration
- Approximately 8 weeks
What is LIB-01 MONOHYDRATE?
LIB-01 MONOHYDRATE is a new medication being developed to treat erectile dysfunction (ED) in adult men. Erectile dysfunction is a condition where a man has difficulty getting or maintaining an erection firm enough for sexual intercourse. This new drug is currently being tested to see if it can help improve sexual function for men with ED.
How Does LIB-01 Work?
While the exact mechanism of action is not fully described in the available information, LIB-01 MONOHYDRATE is being developed as an oral medication to treat erectile dysfunction. It comes in the form of a powder that is mixed into a liquid suspension before taking it by mouth. The drug is designed to help improve a man's ability to get and maintain an erection during sexual activity.
Current Clinical Trial
LIB-01 MONOHYDRATE is currently being studied in a Phase 2a clinical trial. This is an important step in testing new medications to determine if they are safe and effective. The trial is described as:
- Randomized: Participants are randomly assigned to different treatment groups
- Double-blind: Neither the participants nor the researchers know who is receiving which treatment
- Placebo-controlled: Some participants receive an inactive substance (placebo) to compare with the actual medication
The main goal of this trial is to evaluate how well LIB-01 works for treating erectile dysfunction and to assess its safety.
Dosage and Administration
In this clinical trial, researchers are testing three different dose levels of LIB-01 MONOHYDRATE:
- 10 mg once daily for 3 days
- 25 mg once daily for 3 days
- 50 mg once daily for 3 days
The medication is given as an oral suspension, which means the powder is mixed with a liquid before taking it by mouth. Some participants will receive a placebo instead of the active medication for comparison.
Who Can Participate in the Trial?
The trial is looking for men who meet specific criteria, including:
- Age 25 to 65 years old
- In a stable heterosexual relationship for at least 6 months
- Diagnosed with erectile dysfunction based on a questionnaire score
- Highly motivated to seek treatment for ED
There are also several conditions that would exclude someone from participating, such as certain medical histories or medications that might interfere with the study.
Safety Considerations
As with any new medication, safety is a top priority. The researchers will be closely monitoring participants for any side effects or adverse events. They will be checking:
- Vital signs
- Blood tests
- Electrocardiograms (ECGs) to monitor heart activity
Participants will have several follow-up visits to ensure their safety throughout the trial period.
Measuring Effectiveness
To determine how well LIB-01 MONOHYDRATE works, the researchers will use several methods:
- Questionnaires about erectile function and sexual satisfaction
- Tracking successful sexual encounters
- Asking participants if they noticed improvements in their erections
The researchers will compare the results from men taking LIB-01 to those taking the placebo to see if the medication makes a significant difference.
In conclusion, LIB-01 MONOHYDRATE represents a potential new treatment option for men with erectile dysfunction. While it's still in the testing phase, this clinical trial will provide important information about its safety and effectiveness. If successful, it could offer another choice for men seeking help with ED in the future.